VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Other Deferred Liability
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Other Deferred Liability of -$135.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherDeferredLiability · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other deferred liability for the quarter ending 2026-06-30 was -$69.70M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other deferred liability for the quarter ending 2026-03-31 was -$65.30M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other deferred liability for the quarter ending 2025-12-31 was $30.50M, a 40.89% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other deferred liability for the quarter ending 2025-09-30 was -$235.90M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other deferred liability for fiscal 2025 was -$510.80M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other deferred liability for fiscal 2024 was -$348.80M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other deferred liability for fiscal 2023 was -$536.50M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in other deferred liability for fiscal 2022 was -$275.90M.
| Period end | Increase (Decrease) in Other Deferred Liability 3 month | Increase (Decrease) in Other Deferred Liability 3 month as first filed | Increase (Decrease) in Other Deferred Liability 6 month | Increase (Decrease) in Other Deferred Liability 6 month as first filed | Increase (Decrease) in Other Deferred Liability 9 month | Increase (Decrease) in Other Deferred Liability 9 month as first filed | Increase (Decrease) in Other Deferred Liability 12 month | Increase (Decrease) in Other Deferred Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$69.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$135.00M 10-Q · filed 2026-08-04 | -$104.50M derived: sum of 3 quarters · filed 2026-08-04 | -$340.40M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$65.30M 10-Q · filed 2026-05-05 | -$34.80M derived: sum of 2 quarters · filed 2026-05-05 | -$270.70M derived: sum of 3 quarters · filed 2026-05-05 | -$384.50M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $30.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$205.40M derived: sum of 2 quarters · filed 2026-02-13 | -$319.20M derived: sum of 3 quarters · filed 2026-08-04 | -$510.80M 10-K · filed 2026-02-13 | ||||
| 2025-09-30 | -$235.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$349.70M derived: sum of 2 quarters · filed 2026-08-04 | -$541.30M 10-Q · filed 2025-11-04 | -$489.70M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$113.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$305.40M 10-Q · filed 2026-08-04 | -$253.80M derived: sum of 3 quarters · filed 2026-08-04 | -$377.10M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$191.60M 10-Q · filed 2026-05-05 | -$140.00M derived: sum of 2 quarters · filed 2026-05-05 | -$263.30M derived: sum of 3 quarters · filed 2026-05-05 | -$382.10M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $51.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$71.70M derived: sum of 2 quarters · filed 2026-02-13 | -$190.50M derived: sum of 3 quarters · filed 2026-02-13 | -$348.80M 10-K · filed 2026-02-13 | ||||
| 2024-09-30 | -$123.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$242.10M derived: sum of 2 quarters · filed 2025-11-04 | -$400.40M 10-Q · filed 2025-11-04 | -$531.40M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-06-30 | -$118.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$277.10M 10-Q · filed 2025-08-05 | -$408.10M derived: sum of 3 quarters · filed 2026-02-13 | -$523.60M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2024-03-31 | -$158.30M 10-Q · filed 2025-05-06 | -$289.30M derived: sum of 2 quarters · filed 2026-02-13 | -$404.80M derived: sum of 3 quarters · filed 2026-02-13 | -$581.40M derived: sum of 4 quarters · filed 2026-02-13 | ||||
| 2023-12-31 | -$131.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$246.50M derived: sum of 2 quarters · filed 2026-02-13 | -$423.10M derived: sum of 3 quarters · filed 2026-02-13 | -$536.50M 10-K · filed 2026-02-13 | ||||
| 2023-09-30 | -$115.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$292.10M derived: sum of 2 quarters · filed 2024-11-05 | -$405.50M 10-Q · filed 2024-11-05 | -$257.40M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | -$176.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$290.00M 10-Q · filed 2024-08-02 | -$141.90M derived: sum of 3 quarters · filed 2025-02-13 | -$324.20M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | -$113.40M 10-Q · filed 2024-05-07 | $34.70M derived: sum of 2 quarters · filed 2025-02-13 | -$147.60M derived: sum of 3 quarters · filed 2025-02-13 | -$377.00M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | $148.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$34.20M derived: sum of 2 quarters · filed 2025-02-13 | -$263.60M derived: sum of 3 quarters · filed 2025-02-13 | -$275.90M 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | -$182.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$411.70M derived: sum of 2 quarters · filed 2023-11-07 | -$424.00M 10-Q · filed 2023-11-07 | -$465.90M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | -$229.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$241.70M 10-Q · filed 2023-08-02 | -$283.60M derived: sum of 3 quarters · filed 2024-02-15 | -$215.40M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | -$12.30M 10-Q · filed 2023-05-02 | -$54.20M derived: sum of 2 quarters · filed 2024-02-15 | $14.00M derived: sum of 3 quarters · filed 2024-02-15 | -$223.90M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | -$41.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $26.30M derived: sum of 2 quarters · filed 2024-02-15 | -$211.60M derived: sum of 3 quarters · filed 2024-02-15 | -$154.60M 10-K · filed 2024-02-15 | ||||
| 2021-09-30 | $68.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | -$169.70M derived: sum of 2 quarters · filed 2022-10-28 | -$112.70M 10-Q · filed 2022-10-28 | -$112.65M 10-Q · filed 2021-11-03 | $99.49M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-06-30 | -$237.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$180.90M 10-Q · filed 2022-08-05 | -$180.90M 10-Q · filed 2021-07-30 | $31.29M derived: sum of 3 quarters · filed 2023-02-10 | $87.44M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-03-31 | $57.00M 10-Q · filed 2022-05-06 | $57.04M 10-Q · filed 2021-04-30 | $269.19M derived: sum of 2 quarters · filed 2023-02-10 | $325.34M derived: sum of 3 quarters · filed 2023-02-10 | $297.60M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2020-12-31 | $212.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $268.34M derived: sum of 2 quarters · filed 2023-02-10 | $240.59M derived: sum of 3 quarters · filed 2023-02-10 | $277.30M 10-K · filed 2023-02-10 | $277.34M 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $56.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $28.41M derived: sum of 2 quarters · filed 2021-11-03 | $65.11M 10-Q · filed 2021-11-03 | $138.34M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-06-30 | -$27.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $8.96M 10-Q · filed 2021-07-30 | $82.19M derived: sum of 3 quarters · filed 2022-02-09 | $89.00M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2020-03-31 | $36.70M 10-Q · filed 2021-04-30 | $109.93M derived: sum of 2 quarters · filed 2022-02-09 | $116.75M derived: sum of 3 quarters · filed 2022-02-09 | $160.68M derived: sum of 4 quarters · filed 2022-02-09 | ||||
| 2019-12-31 | $73.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $80.04M derived: sum of 2 quarters · filed 2022-02-09 | $123.97M derived: sum of 3 quarters · filed 2022-02-09 | $167.40M 10-K · filed 2022-02-09 | $167.39M 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $6.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $50.75M derived: sum of 2 quarters · filed 2020-10-30 | $94.17M 10-Q · filed 2020-10-30 | -$1.42B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $43.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $87.36M 10-Q · filed 2020-07-31 | -$1.43B derived: sum of 3 quarters · filed 2021-02-11 | -$1.43B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $43.42M 10-Q · filed 2020-05-01 | -$1.47B derived: sum of 2 quarters · filed 2021-02-11 | -$1.47B derived: sum of 3 quarters · filed 2021-02-11 | -$1.47B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | -$1.52B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | -$1.52B derived: sum of 2 quarters · filed 2021-02-11 | -$1.52B derived: sum of 3 quarters · filed 2021-02-11 | -$1.51B 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $79.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $8.00K derived: sum of 2 quarters · filed 2019-10-31 | $3.60M 10-Q · filed 2019-10-31 | -$2.95M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | -$71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $3.52M 10-Q · filed 2019-08-01 | -$3.03M derived: sum of 3 quarters · filed 2020-02-13 | -$121.62M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $3.59M 10-Q · filed 2019-05-01 | -$2.96M derived: sum of 2 quarters · filed 2020-02-13 | -$121.55M derived: sum of 3 quarters · filed 2020-02-13 | -$118.14M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | -$6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$125.14M derived: sum of 2 quarters · filed 2020-02-13 | -$121.72M derived: sum of 3 quarters · filed 2020-02-13 | -$120.51M 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | -$118.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | -$115.18M derived: sum of 2 quarters · filed 2018-10-25 | -$113.97M 10-Q · filed 2018-10-25 | -$120.55M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-06-30 | $3.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $4.63M 10-Q · filed 2018-07-26 | -$1.96M derived: sum of 3 quarters · filed 2019-02-13 | -$1.27M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-03-31 | $1.21M 10-Q · filed 2018-04-27 | -$5.37M derived: sum of 2 quarters · filed 2019-02-13 | -$4.68M derived: sum of 3 quarters · filed 2019-02-13 | $16.11M derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2016-12-31 | -$6.58M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | -$5.90M derived: sum of 2 quarters · filed 2019-02-13 | $14.90M derived: sum of 3 quarters · filed 2019-02-13 | $16.96M 10-K · filed 2019-02-13 | ||||
| 2016-09-30 | $686.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $21.48M derived: sum of 2 quarters · filed 2017-10-30 | $23.54M 10-Q · filed 2017-10-30 | $19.03M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-06-30 | $20.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $22.86M 10-Q · filed 2017-07-28 | $18.35M derived: sum of 3 quarters · filed 2018-02-15 | $19.80M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-03-31 | $2.06M 10-Q · filed 2017-04-28 | -$2.45M derived: sum of 2 quarters · filed 2018-02-15 | -$1.00M derived: sum of 3 quarters · filed 2018-02-15 | $5.34M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2015-12-31 | -$4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$3.06M derived: sum of 2 quarters · filed 2018-02-15 | $3.28M derived: sum of 3 quarters · filed 2018-02-15 | $3.28M 10-K · filed 2018-02-15 | ||||
| 2015-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | $7.79M derived: sum of 2 quarters · filed 2016-10-31 | $7.79M 10-Q · filed 2016-10-31 | $8.07M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $6.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $6.35M 10-Q · filed 2016-08-01 | $6.63M derived: sum of 3 quarters · filed 2017-02-23 | $6.63M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-03 | $281.00K derived: sum of 2 quarters · filed 2017-02-23 | $281.00K derived: sum of 3 quarters · filed 2017-02-23 | $281.00K derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2014-12-31 | $281.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $281.00K derived: sum of 2 quarters · filed 2017-02-23 | $281.00K derived: sum of 3 quarters · filed 2017-02-23 | $281.00K 10-K · filed 2017-02-23 | ||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $0.00 derived: sum of 2 quarters · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | -$154.89M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $0.00 10-Q · filed 2015-08-04 | -$154.89M derived: sum of 3 quarters · filed 2016-02-16 | -$154.39M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-05 | -$154.89M derived: sum of 2 quarters · filed 2016-02-16 | -$154.39M derived: sum of 3 quarters · filed 2016-02-16 | -$156.35M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2013-12-31 | -$154.89M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | -$154.39M derived: sum of 2 quarters · filed 2016-02-16 | -$156.35M derived: sum of 3 quarters · filed 2016-02-16 | -$285.05M 10-K · filed 2016-02-16 | ||||
| 2013-09-30 | $497.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$1.46M derived: sum of 2 quarters · filed 2014-11-06 | -$130.16M 10-Q · filed 2014-11-06 | -$129.26M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-06-30 | -$1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$130.66M 10-Q · filed 2014-07-31 | -$129.76M derived: sum of 3 quarters · filed 2015-02-13 | -$113.31M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2013-03-31 | -$128.70M 10-Q · filed 2014-05-05 | -$127.80M derived: sum of 2 quarters · filed 2015-02-13 | -$111.35M derived: sum of 3 quarters · filed 2015-02-13 | -$89.76M derived: sum of 4 quarters · filed 2015-02-13 | ||||
| 2012-12-31 | $901.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $17.35M derived: sum of 2 quarters · filed 2015-02-13 | $38.94M derived: sum of 3 quarters · filed 2015-02-13 | $36.66M 10-K · filed 2015-02-13 | ||||
| 2012-09-30 | $16.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $38.04M derived: sum of 2 quarters · filed 2013-11-07 | $35.76M 10-Q · filed 2013-11-07 | $46.50M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | $21.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $19.31M 10-Q · filed 2013-08-02 | $30.05M derived: sum of 3 quarters · filed 2014-02-11 | $2.48M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | -$2.28M 10-Q · filed 2013-05-08 | $8.46M derived: sum of 2 quarters · filed 2014-02-11 | -$19.11M derived: sum of 3 quarters · filed 2014-02-11 | |||||
| 2011-12-31 | $10.74M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$16.83M derived: sum of 2 quarters · filed 2014-02-11 | -$7.50M 10-K · filed 2014-02-11 | |||||
| 2011-09-30 | -$27.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$18.24M 10-Q · filed 2012-11-06 | ||||||
| 2011-06-30 | $9.33M 10-Q · filed 2012-08-08 | |||||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 | |||||||
| 2009-12-31 | -$2.23M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |